Kristopher Hanson sold $419k of MPLT
General Counsel at MapLight Therapeutics, Inc.. 13,917 shares at an average of $30.13, traded May 11, 2026, filed May 11, 2026.
Score components
- +15RoleOfficer
- +16Trade size$419k at market
- 0Share of holdings soldSold 7.9% of holdings
- +15Cluster7 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001789970-26-000010, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 11, 2026 | SOpen-market sale Voting Common Stock10b5-1 | -284 | $27.61 | $7,841 | 175,964 | May 11, 2026 |
| May 11, 2026 | SOpen-market sale Voting Common Stock10b5-1 | -846 | $28.70 | $24k | 175,118 | May 11, 2026 |
| May 11, 2026 | SOpen-market sale Voting Common Stock10b5-1 | -6,979 | $30.04 | $210k | 168,139 | May 11, 2026 |
| May 11, 2026 | SOpen-market sale Voting Common Stock10b5-1 | -5,808 | $30.56 | $177k | 162,331 | May 11, 2026 |
Related signals
Other insiders at MapLight Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 12Weak | MapLight Therapeutics, Inc. | Kristopher Hanson General Counsel | $193k 16,509 shares | -11% | |
| 51Moderate | MPLTbuy MapLight Therapeutics, Inc. | Catalyst4, Inc. owner | $50M 4,400,000 shares | +21% | |
| 9Weak | MapLight Therapeutics, Inc. | James Woodruff Lillie Chief Scientific Officer | $277k 22,082 shares | -10% | |
| 51Moderate | MapLight Therapeutics, Inc. | Catalyst4, Inc. owner | $15M 1,209,225 shares | +6% | |
| 50Moderate | MapLight Therapeutics, Inc. | Troy Cox director | $149k 15,620 shares | - | |
| 47Moderate | MapLight Therapeutics, Inc. | Jonathan Gillis CAO and Interim CFO | $1.4M 36,979 shares | -20% | |
| 40Moderate | MapLight Therapeutics, Inc. | Anatol Kreitzer Chief Discovery Officer | $1.3M 36,284 shares | -17% | |
| 40Moderate | MapLight Therapeutics, Inc. | Erin Pennock Foff Chief Medical Officer | $1.7M 47,158 shares | -14% | |
| 55Moderate | MapLight Therapeutics, Inc. | Kristopher Hanson General Counsel | $608k 16,508 shares | -10% | |
| 70Notable | MapLight Therapeutics, Inc. | Christopher A. Kroeger Chief Executive Officer | $5.4M 147,639 shares | -11% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.